Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные принципы применения левофлоксацина в лечении инфекций кожи и мягких тканей
В.Б.Белобородов. Современные принципы применения левофлоксацина в лечении инфекций кожи и мягких тканей. Consilium Medicum. Хирургия (Прил.). 2009; 1: 38-41.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Graham DR. e.a. Clin Infect Dis. 2002; 35: 381–9.
2. Overholser BR, Kays MB, Lagvankar S et al. Pharmacokinetics of IntravenouslyAdministered Levofloxacin in Men and Women. Pharmacotherapy 2005; 25 (10): 1310–8.
3. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of Intravenous and Oral Levofloxacin in Critcally Ill Adults in a Medical Intensive Care Unit. Pharmacotherapy 2002; 22 (10): 1216–25.
4. Gander S. Bacterial biofilms: resistance to antimicrobial agents. J Antimicrob Chemother 1996; 37: 1047–50.
5. Dickinson GM, Bisno AL. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob Agents Chemother 1989; 33: 597–601.
6. Hamilton-Miller JMT, Shah S. Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. J Antimicrob Chemother 1997; 39 (suppl. A): 103–8.
7. Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterials. Antimicrob Agents Chemother 1990; 34: 2043–6.
8. Farber BF, Kaplan MH, Clogston AG. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis 1990; 161: 37–40.
9. Pascual A, Garcia I, Ramirez de Arellano E, Perea EJ. Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters. J Antimicrob Chemother 1995; 36: 425–30.
10. Gagnon RF, Richards GK, Kostiner GB. Time-kill efficacy of antibiotics in combination with rifampin against Staphylococcus epidermidis biofilms. Adv Perit Dial 1994; 10: 189–92.
11. Pascual A, Ramirez de Arellano E, Perea EJ. Activity of glycopeptides in combination with amikacin or rifampin against Staphylococcus epidermidis biofilms on plastic catheters. Eur J Clin Microbiol Infect Dis 1994; 13: 515–7.
12. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 1998; 279: 1537–41.
13. Kang-Birken L. Comparative In Vitro Activity of Vancomycin and Levofloxacin in Combination with Rifampin Against Planktonic versus Sessile Cells of Staphylococcus epidermidis. Pharmacotherapy 2000; 20 (6): 673–8.
14. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53 (Suppl. 2): ii37–50.
15. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63 (14): 1459–80.
16. Centers for Disease Control and Prevention. Summary of provisional cases of selected notifiable diseases United States cumulative week ending 2000 Dec 30. MMWR Morb Mortal Wkly Rep 2001; 49 (51): 1167.
17. Centers for Disease Control and Prevention. Summary of provisional cases of selected notifiable diseases United States cumulative week ending 2000 Dec 30. MMWR Morb Mortal Wkly Rep 2001; 50 (51): 1169.
18. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol 1999; 26 (3–4): 267–76.
19. Baddour LM, Bisno AL. Non group A beta hemolytic streptococcal cellulitis: association with venous and lymphatic compromise. Am J Med 1985; 79: 155–9.
20. Dong SL, Kelly KD, Oland RC et al. ED management of cellulitis: a review of five urban centers. Am J Emerg Med 2001; 19 (7): 535–40.
21. Jones ME, Karlowsky JA, Draghi DC et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22 (4): 406–19.
22. Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician 2002; 66 (1): 119–24.
23. Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004; 350 (9): 904–12.
24. Guay DR. Treatment of bacterial skin and skin structure infections. Expert Opin Pharmacother 2003; 4 (8): 1259–75.
25. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004; 64 (15): 1621–42.
26. Blondeau JM. The role of fluoroquinolones in skin and skin structure infections. Am J Clin Dermatol 2002; 3 (1): 37–46.
27. Martin SJ, Zeigler DG. The use of fluoroquinolones in the treatment of skin infections. Expert Opin Pharmacother 2004; 5 (2): 237–46.
28. Wenzler S, Schmidt-Eisenlohr E, Daschner F. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. Chemotherapy 2004; 50: 40–2.
29. Milatovic D, Schmitz FJ, Brisse S et al. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 2000; 44 (4): 1102–7.
30. Noguchi N, Okihara T, Namiki Y et al. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents 2005; 25 (5): 374–9.
31. Keating KN, Friedman H, Perfetto EM. Fluoroquinolone Therapy for Uncomplicated Skin and Skin Structure Infections. Clin Drug Invest 2005; 25 (10): 621–13.
2. Overholser BR, Kays MB, Lagvankar S et al. Pharmacokinetics of IntravenouslyAdministered Levofloxacin in Men and Women. Pharmacotherapy 2005; 25 (10): 1310–8.
3. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of Intravenous and Oral Levofloxacin in Critcally Ill Adults in a Medical Intensive Care Unit. Pharmacotherapy 2002; 22 (10): 1216–25.
4. Gander S. Bacterial biofilms: resistance to antimicrobial agents. J Antimicrob Chemother 1996; 37: 1047–50.
5. Dickinson GM, Bisno AL. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob Agents Chemother 1989; 33: 597–601.
6. Hamilton-Miller JMT, Shah S. Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. J Antimicrob Chemother 1997; 39 (suppl. A): 103–8.
7. Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterials. Antimicrob Agents Chemother 1990; 34: 2043–6.
8. Farber BF, Kaplan MH, Clogston AG. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis 1990; 161: 37–40.
9. Pascual A, Garcia I, Ramirez de Arellano E, Perea EJ. Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters. J Antimicrob Chemother 1995; 36: 425–30.
10. Gagnon RF, Richards GK, Kostiner GB. Time-kill efficacy of antibiotics in combination with rifampin against Staphylococcus epidermidis biofilms. Adv Perit Dial 1994; 10: 189–92.
11. Pascual A, Ramirez de Arellano E, Perea EJ. Activity of glycopeptides in combination with amikacin or rifampin against Staphylococcus epidermidis biofilms on plastic catheters. Eur J Clin Microbiol Infect Dis 1994; 13: 515–7.
12. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 1998; 279: 1537–41.
13. Kang-Birken L. Comparative In Vitro Activity of Vancomycin and Levofloxacin in Combination with Rifampin Against Planktonic versus Sessile Cells of Staphylococcus epidermidis. Pharmacotherapy 2000; 20 (6): 673–8.
14. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53 (Suppl. 2): ii37–50.
15. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63 (14): 1459–80.
16. Centers for Disease Control and Prevention. Summary of provisional cases of selected notifiable diseases United States cumulative week ending 2000 Dec 30. MMWR Morb Mortal Wkly Rep 2001; 49 (51): 1167.
17. Centers for Disease Control and Prevention. Summary of provisional cases of selected notifiable diseases United States cumulative week ending 2000 Dec 30. MMWR Morb Mortal Wkly Rep 2001; 50 (51): 1169.
18. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol 1999; 26 (3–4): 267–76.
19. Baddour LM, Bisno AL. Non group A beta hemolytic streptococcal cellulitis: association with venous and lymphatic compromise. Am J Med 1985; 79: 155–9.
20. Dong SL, Kelly KD, Oland RC et al. ED management of cellulitis: a review of five urban centers. Am J Emerg Med 2001; 19 (7): 535–40.
21. Jones ME, Karlowsky JA, Draghi DC et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22 (4): 406–19.
22. Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician 2002; 66 (1): 119–24.
23. Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004; 350 (9): 904–12.
24. Guay DR. Treatment of bacterial skin and skin structure infections. Expert Opin Pharmacother 2003; 4 (8): 1259–75.
25. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004; 64 (15): 1621–42.
26. Blondeau JM. The role of fluoroquinolones in skin and skin structure infections. Am J Clin Dermatol 2002; 3 (1): 37–46.
27. Martin SJ, Zeigler DG. The use of fluoroquinolones in the treatment of skin infections. Expert Opin Pharmacother 2004; 5 (2): 237–46.
28. Wenzler S, Schmidt-Eisenlohr E, Daschner F. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. Chemotherapy 2004; 50: 40–2.
29. Milatovic D, Schmitz FJ, Brisse S et al. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 2000; 44 (4): 1102–7.
30. Noguchi N, Okihara T, Namiki Y et al. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents 2005; 25 (5): 374–9.
31. Keating KN, Friedman H, Perfetto EM. Fluoroquinolone Therapy for Uncomplicated Skin and Skin Structure Infections. Clin Drug Invest 2005; 25 (10): 621–13.
Авторы
В.Б.Белобородов
Российская медицинская академия последипломного образования, Москва
Российская медицинская академия последипломного образования, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.